SSY GROUP (02005.HK): noradrenaline 1ml:2mg wins NMPA approval

On 17 November 2026, SSY GROUP (02005.HK) won approval for norepinephrine bitartrate 1ml:2mg and a new postoperative pain indication for paracetamol injection.
Key Highlights:
  • Norepinephrine bitartrate injection 1ml:2mg was approved as a Category 3 chemical drug deemed to have passed consistency evaluation.
  • The Group offers four adrenaline-class injections with four self-supplied APIs; domestic annual use is estimated at about 200 million vials.

NewTimeSpace News: On 17 November 2026, SSY Group Limited (stock code: 02005) said it obtained NMPA approval to produce norepinephrine bitartrate injection (1ml:2mg), a Category 3 chemical drug deemed to have passed generic consistency evaluation, mainly for blood pressure control in certain acute hypotensive states.

The 4ml:8mg strength was approved earlier; the smaller strength better suits initial dosing, down-titration and paediatric use. Annual domestic use of adrenaline-class emergency medicines is estimated at about 200 million vials. The Group now offers four such injections and self-supplies the four corresponding APIs. Separately, paracetamol and mannitol injection (50ml and 100ml) won approval for a new indication, relieving moderate to severe postoperative pain in adults with opioid analgesics, adding to its existing antipyretic use; the Group is the first in China approved for both uses.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.